The Oasis Group and Practifi Release White Paper on CRM Selection in Wealth Management
Leading industry research provider and CRM platform partner to deliver practical roadmap for financial advisors beyond the build-vs-buy decision FORT MILL, S.C.–(BUSINESS... Read more.
SkyWater Technology to Announce Fourth Quarter Financial Results on February 25, 2026
BLOOMINGTON, Minn.–(BUSINESS WIRE)–SkyWater Technology (NASDAQ: SKYT), the largest U.S.-based, pure-play semiconductor foundry, will report its fiscal... Read more.
GCT Semiconductor Partners with Skylo to Accelerate Global Satellite Connectivity
The companies are collaborating to expand seamless global satellite connectivity for next-generation cellular IoT devices, including joint efforts towards chip and... Read more.
Ryder Reports Fourth Quarter 2025 Results and Provides 2026 Outlook
Transformed Business Model Continues to Outperform Prior Cycles; Upsized Strategic Initiatives Expected to Drive 2026 Earnings Growth Fourth Quarter 2025 Highlights... Read more.
AECOM to provide detailed design services to support delivery of Sydney Metro West
DALLAS–(BUSINESS WIRE)–AECOM (NYSE: ACM), the trusted global infrastructure leader, today announced it will deliver detailed design services for the... Read more.
CHIMERA INVESTMENT CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2025 EARNINGS
NEW YORK–(BUSINESS WIRE)–Chimera Investment Corporation (NYSE:CIM) today announced its financial results for the fourth quarter and full year ended December... Read more.
Ferguson to Issue Results for the Period Ended December 31, 2025, as well as provide an Update on Market Opportunities and Strategy on February 24, 2026
NEWPORT NEWS, Va.–(BUSINESS WIRE)–Ferguson Enterprises Inc. (NYSE: FERG; LSE: FERG) announces today that it will issue its results for the period ended... Read more.
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal... Read more.
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
Approval expands first-line PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2 SANTA CLARA, Calif.–(BUSINESS WIRE)–$A #BringGreatScienceToLife—Agilent... Read more.
Chimera Increases First Quarter 2026 Common Stock Dividend to $0.45 and Declares First Quarter 2026 Preferred Stock Dividends
BOARD DECLARES FIRST QUARTER 2026 DIVIDEND OF $0.45 PER SHARE OF COMMON STOCK BOARD EXPECTS CHIMERA TO MAINTAIN A QUARTERLY DIVIDEND OF $0.45 PER COMMON SHARE FOR... Read more.